The latest price target for Syros Pharmaceuticals (NASDAQ:SYRS) was reported by TD Cowen on November 13, 2024. The analyst firm set a price target for $0.00 expecting SYRS to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Syros Pharmaceuticals (NASDAQ:SYRS) was provided by TD Cowen, and Syros Pharmaceuticals downgraded their hold rating.

There is no last upgrade for Syros Pharmaceuticals

The last downgrade for Syros Pharmaceuticals Inc happened on November 13, 2024 when TD Cowen changed their price target from N/A to N/A for Syros Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $0.18, which is out of the analyst’s predicted range.